THU0264 In Early Rheumatoid Arthritis (Espoir Cohort), Serum CCL19 Level is Associated with Disease Activity, Autoantibody Secretion and 3-Year Radiographic Progression: Data from the Espoir Cohort. (10th June 2014)

• Record Type: Journal Article
• Authors: Gottenberg, J.E.; Seror, R.; Baillet, A.; Rincheval, N.; Alsaleh, G.; Pichot, A.; Schaeverbeke, T.; Cantagrel, A.; Combe, B.; Mariette, X.
• Is Part Of: Annals of the rheumatic diseases. Volume 73:Supplement 2(2014)
• Page Start: 274
• Page End: 274
• Publication Date: 2014-06-10
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2014-eular.4239
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: The interferon (IFN) signature has mainly been studied in established rheumatoid arthritis (RA), and was associated with poor response to rituximab. Serum levels of CCL2 (Monocyte Chemotactic Protein 1, MCP-1), CXCL10 (Interferon gamma –inducible 10 kDa Protein, IP-10) and CCL19 (Macrophage Inflammatory Protein 3 beta, MIP-3beta) are associated with an interferon (IFN) gene signature and disease activity in systemic lupus. Objectives: The objectives of the study were to assess the association between the IFN serum signature, disease activity, autoantibody secretion, radiographic progression and rapid initiation of a biologic DMARD in early RA. Methods: Serum levels of CCL2, CXCL10, and CCL19 were assessed in the ESPOIR cohort composed of 813 patients with early arthritis (more than 6 weeks and less than 6 months) not treated with steroid or DMARD. RA was defined according to ACR/EULAR 2010 criteria. An elevated level of each chemokine was defined as a value greater than the mean + 2DS value of the control population (88 sex and age-matched subjects). Patients with at least 2 out of 3 IFN-regulated chemokines were defined to have an IFN-high score. Results: Among the 813 patients included in the ESPOIR cohort, 641 patients had RA according to ACR/EULAR 2010 criteria. Elevated levels of CCL2, CXCL10, CCL19 were observed in 1.9% of early RA patients vs 0.6% of patients with other early arthritides ( P =0.5), 49.4 vs 38.2% (P=0.01) and 23.3 vs 7.1% (P<0.0001), respectively. An IFN-high score was observed in 15.1% of RA patients vs 2.9% of patients with other early arthritides (P<0.0001). Among the 641 patients with RA according to ACR/EULAR 2010 criteria, CXCL10 and CCL19 were significantly correlated with DAS28 at enrollment (r=0.22 and r=0.16, respectively, P <0.0001 for both) whereas CCL2 was not. Patients with RF or anti-CCP autoantibodies only had elevated levels of CCL19 (315.5[142.6-631.6] vs 214.4 [101.2-443.0] pg/ml, P <0.0001 and 332.6 [161.1-645.8] vs 214.5 [96.4-447.6] pg/ml, P <0.0001) whereas they had similar CCL2 and CXCL10 levels. RF and anti-CCP positivity were not associated with IFN-high score. Radiographic progression at 3 years (increase of total Sharp score greater than 5) was only associated with increased levels of CCL19 ( P =0.05) but not with CCL2 or CXCL10, or with IFN-high score. Initiation of a biologic DMARD within the first year after enrollment was only significantly associated with increased levels of CCL19 (391.8 [197.3-548.6] vs 263.1[166.4-533.8] pg/ml, P =0.03 ). Conclusions: In early RA, serum CCL19 level is associated with disease activity, autoantibody secretion and 3-year radiographic progression. Patients with a high-IFN serum signature represent 15% of patients with early RA, with a rather good prognosis since high-IFN serum signature was not associated with autoantibody secretion, radiographic progression, or rapid initiation of a biologic DMARD treatment of RA. Disclosure of Interest: : None declared DOI: 10.1136/annrheumdis-2014-eular.4239